DOCSLIB.ORG

NDA/BLA Multi-Disciplinary Review and Evaluation

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
NDA/BLA Multi-Disciplinary Review and Evaluation NDA/BLA Multi-disciplinary Review and Evaluation NDA 214154 Nextstellis (drospirenone and estetrol tablets) NDA/BLA Multi-Disciplinary Review and Evaluation Application Type NDA Application Number(s) NDA 214154 (IND 110682) Priority or Standard Standard Submit Date(s) April 15, 2020 Received Date(s) April 15, 2020 PDUFA Goal Date April 15, 2021 Division/Office Division of Urology, Obstetrics, and Gynecology (DUOG) / Office of Rare Diseases, Pediatrics, Urologic and Reproductive Medicine (ORPURM) Review Completion Date April 15, 2021 Established/Proper Name drospirenone and estetrol tablets (Proposed) Trade Name Nextstellis Pharmacologic Class Combination hormonal contraceptive Applicant Mayne Pharma LLC Dosage form Tablet Applicant proposed Dosing x Take one tablet by mouth at the same time every day. Regimen x Take tablets in the order directed on the blister pack. Applicant Proposed For use by females of reproductive potential to prevent Indication(s)/Population(s) pregnancy Recommendation on Approval Regulatory Action Recommended For use by females of reproductive potential to prevent Indication(s)/Population(s) pregnancy (if applicable) Recommended Dosing x Take one pink tablet (drospirenone 3 mg, estetrol Regimen anhydrous 14.2 mg) by mouth at the same time every day for 24 days x Take one white inert tablet (placebo) by mouth at the same time every day for 4 days following the pink tablets x Take tablets in the order directed on the blister pack 1 Reference ID: 4778993 NDA/BLA Multi-disciplinary Review and Evaluation NDA 214154 Nextstellis (drospirenone and estetrol tablets) Table of Contents Table of Tables .................................................................................................................... 5 Table of Figures ................................................................................................................... 7 Reviewers of Multi-Disciplinary Review and Evaluation .................................................... 8 Glossary ............................................................................................................................. 12 1. Executive Summary ....................................................................................................... 15 Product Introduction .............................................................................................. 15 Conclusions on the Substantial Evidence of Effectiveness .................................... 16 Benefit-Risk Assessment ........................................................................................ 20 Patient Experience Data ......................................................................................... 24 2. Therapeutic Context ..................................................................................................... 26 Analysis of Condition .............................................................................................. 26 Analysis of Current Treatment Options ................................................................. 26 3. Regulatory Background ................................................................................................. 28 U.S. Regulatory Actions and Marketing History ..................................................... 28 Summary of Presubmission/Submission Regulatory Activity ................................ 28 4. Significant Issues From Other Review Disciplines Pertinent to Clinical Conclusions on Efficacy and Safety ............................................................................. 30 Office of Scientific Investigations (OSI) .................................................................. 30 Product Quality....................................................................................................... 31 Clinical Microbiology .............................................................................................. 32 Devices and Companion Diagnostic Issues ............................................................ 33 5. Nonclinical Pharmacology/Toxicology .......................................................................... 33 Executive Summary ................................................................................................ 33 Referenced NDAs, BLAs, DMFs............................................................................... 42 Pharmacology ......................................................................................................... 42 Primary Pharmacology of Estetrol Monohydrate ............................................ 42 Secondary Pharmacology of Estetrol Monohydrate ....................................... 44 Safety Pharmacology of Estetrol Monohydrate .............................................. 45 Pharmacology of Drospirenone ....................................................................... 46 ADME/PK ................................................................................................................ 47 Pharmacokinetics of Estetrol Monohydrate.................................................... 47 Pharmacokinetics of Drospirenone ................................................................. 60 Toxicology ............................................................................................................... 61 General Toxicology of Estetrol Monohydrate ................................................. 61 2 Reference ID: 4778993 NDA/BLA Multi-disciplinary Review and Evaluation NDA 214154 Nextstellis (drospirenone and estetrol tablets) General Toxicology of Combined Estetrol Monohydrate and Drospirenone ................................................................................................. 66 Genetic Toxicology of Estetrol Monohydrate .................................................. 69 Carcinogenicity of Estetrol Monohydrate ....................................................... 73 Reproductive and Developmental Toxicology of Estetrol Monohydrate ........ 74 Other Toxicology Studies of Estetrol Monohydrate ........................................ 83 Summary of Toxicity of Drospirenone ............................................................. 83 6. Clinical Pharmacology ................................................................................................... 84 Executive Summary ................................................................................................ 84 Summary of Clinical Pharmacology Assessment .................................................... 85 Pharmacology and Clinical Pharmacokinetics ................................................. 85 General Dosing and Therapeutic Individualization ......................................... 88 Comprehensive Clinical Pharmacology Review ..................................................... 90 General Pharmacology and Pharmacokinetic Characteristics ......................... 90 Clinical Pharmacology Questions .................................................................... 91 7. Sources of Clinical Data and Review Strategy ............................................................... 98 Table of Clinical Studies .......................................................................................... 98 Review Strategy.................................................................................................... 107 8. Statistical and Clinical and Evaluation ........................................................................ 107 Review of Relevant Individual Trials Used to Support Efficacy ............................ 107 Study MIT-Es0001-C302 (Study C302) ........................................................... 107 Study Results .................................................................................................. 112 Supportive Effectiveness Information From Study C301 .............................. 121 Integrated Assessment of Effectiveness ........................................................ 124 Review of Safety ................................................................................................... 124 Safety Review Approach ................................................................................ 124 Review of the Safety Database ...................................................................... 125 Adequacy of Applicant’s Clinical Safety Assessments ................................... 129 Safety Results ................................................................................................. 131 Analysis of Submission-Specific Safety Issues ............................................... 142 Clinical Outcome Assessment (COA) Analyses Informing Safety/Tolerability ....................................................................................... 145 Safety Analyses by Demographic Subgroups................................................. 145 Specific Safety Studies/Clinical Trials............................................................. 146 Additional Safety Explorations ...................................................................... 146 Safety in the Postmarket Setting ................................................................. 147 3 Reference ID: 4778993 NDA/BLA Multi-disciplinary Review and Evaluation NDA 214154 Nextstellis (drospirenone and estetrol tablets) Integrated Assessment of Safety................................................................. 147 Statistical Issues .................................................................................................... 148 Conclusions and Recommendations
Load more

Recommended publications
  • ECO-Ssls for Pahs
    Ecological Soil Screening Levels for Polycyclic Aromatic Hydrocarbons (PAHs) Interim Final OSWER Directive 9285.7-78 U.S. Environmental Protection Agency Office of Solid Waste and Emergency Response 1200 Pennsylvania Avenue, N.W. Washington, DC 20460 June 2007 This page intentionally left blank TABLE OF CONTENTS 1.0 INTRODUCTION .......................................................1 2.0 SUMMARY OF ECO-SSLs FOR PAHs......................................1 3.0 ECO-SSL FOR TERRESTRIAL PLANTS....................................4 5.0 ECO-SSL FOR AVIAN WILDLIFE.........................................8 6.0 ECO-SSL FOR MAMMALIAN WILDLIFE..................................8 6.1 Mammalian TRV ...................................................8 6.2 Estimation of Dose and Calculation of the Eco-SSL ........................9 7.0 REFERENCES .........................................................16 7.1 General PAH References ............................................16 7.2 References Used for Derivation of Plant and Soil Invertebrate Eco-SSLs ......17 7.3 References Rejected for Use in Derivation of Plant and Soil Invertebrate Eco-SSLs ...............................................................18 7.4 References Used in Derivation of Wildlife TRVs .........................25 7.5 References Rejected for Use in Derivation of Wildlife TRV ................28 i LIST OF TABLES Table 2.1 PAH Eco-SSLs (mg/kg dry weight in soil) ..............................4 Table 3.1 Plant Toxicity Data - PAHs ..........................................5 Table 4.1
    [Show full text]
  • Biosynthesis and Secretion of the Microbial Sulfated Peptide Raxx and Binding to the Rice XA21 Immune Receptor
    Biosynthesis and secretion of the microbial sulfated peptide RaxX and binding to the rice XA21 immune receptor Dee Dee Luua,b,1, Anna Joea,b,c,1, Yan Chend, Katarzyna Paryse, Ofir Bahara,b,2, Rory Pruitta,b,3, Leanne Jade G. Chand, Christopher J. Petzoldd, Kelsey Longa,b, Clifford Adamchaka,b, Valley Stewartf, Youssef Belkhadire, and Pamela C. Ronalda,b,c,4 aDepartment of Plant Pathology, University of California, Davis, CA 95616; bThe Genome Center, University of California, Davis, CA 95616; cFeedstocks Division, Joint Bioenergy Institute, Emeryville, CA 94608; dTechnology Division, Joint Bioenergy Institute, Emeryville, CA 94608; eGregor Mendel Institute, Austrian Academy of Sciences, 1030 Vienna, Austria; and fDepartment of Microbiology & Molecular Genetics, University of California, Davis, CA 95616 Edited by Jonathan D. G. Jones, The Sainsbury Laboratory, Norwich, United Kingdom, and approved March 7, 2019 (received for review October 24, 2018) The rice immune receptor XA21 is activated by the sulfated micro- to Xoo strains lacking RaxX (7–10). Xoo strains lacking RaxX are bial peptide required for activation of XA21-mediated immunity X also compromised in virulence of rice plants lacking XA21 (10). (RaxX) produced by Xanthomonas oryzae pv. oryzae (Xoo). Muta- These results suggest a role for RaxX in bacterial virulence. tional studies and targeted proteomics revealed that the RaxX pre- Tyrosine sulfated RaxX16, a 16-residue synthetic peptide de- cursor peptide (proRaxX) is processed and secreted by the protease/ rived from residues 40–55 of the 60-residue RaxX precursor transporter RaxB, the function of which can be partially fulfilled by peptide (proRaxX), is the shortest characterized immunogenic a noncognate peptidase-containing transporter component B derivative of RaxX (10).
    [Show full text]
  • Memorandum Date: June 6, 2014
    DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service Food and Drug Administration Memorandum Date: June 6, 2014 From: Bisphenol A (BPA) Joint Emerging Science Working Group Smita Baid Abraham, M.D. ∂, M. M. Cecilia Aguila, D.V.M. ⌂, Steven Anderson, Ph.D., M.P.P.€* , Jason Aungst, Ph.D.£*, John Bowyer, Ph.D. ∞, Ronald P Brown, M.S., D.A.B.T.¥, Karim A. Calis, Pharm.D., M.P.H. ∂, Luísa Camacho, Ph.D. ∞, Jamie Carpenter, Ph.D.¥, William H. Chong, M.D. ∂, Chrissy J Cochran, Ph.D.¥, Barry Delclos, Ph.D.∞, Daniel Doerge, Ph.D.∞, Dongyi (Tony) Du, M.D., Ph.D. ¥, Sherry Ferguson, Ph.D.∞, Jeffrey Fisher, Ph.D.∞, Suzanne Fitzpatrick, Ph.D. D.A.B.T. £, Qian Graves, Ph.D.£, Yan Gu, Ph.D.£, Ji Guo, Ph.D.¥, Deborah Hansen, Ph.D. ∞, Laura Hungerford, D.V.M., Ph.D.⌂, Nathan S Ivey, Ph.D. ¥, Abigail C Jacobs, Ph.D.∂, Elizabeth Katz, Ph.D. ¥, Hyon Kwon, Pharm.D. ∂, Ifthekar Mahmood, Ph.D. ∂, Leslie McKinney, Ph.D.∂, Robert Mitkus, Ph.D., D.A.B.T.€, Gregory Noonan, Ph.D. £, Allison O’Neill, M.A. ¥, Penelope Rice, Ph.D., D.A.B.T. £, Mary Shackelford, Ph.D. £, Evi Struble, Ph.D.€, Yelizaveta Torosyan, Ph.D. ¥, Beverly Wolpert, Ph.D.£, Hong Yang, Ph.D.€, Lisa B Yanoff, M.D.∂ *Co-Chair, € Center for Biologics Evaluation & Research, £ Center for Food Safety and Applied Nutrition, ∂ Center for Drug Evaluation and Research, ¥ Center for Devices and Radiological Health, ∞ National Center for Toxicological Research, ⌂ Center for Veterinary Medicine Subject: 2014 Updated Review of Literature and Data on Bisphenol A (CAS RN 80-05-7) To: FDA Chemical and Environmental Science Council (CESC) Office of the Commissioner Attn: Stephen M.
    [Show full text]
  • Estetrol: New Perspectives for HRT in Menopause and Breast Cancer
    Graziottin A. Singer C. Kubista E. Visser M. Coelingh Bennink H. Estetrol: new perspectives for HRT in menopause and breast cancer patients V Annual International Congress on Human Reproduction on "Family Reproductive Health", Moscow, Russia, January 18-21, 2011 Estetrol: new perspectives for HRT in menopause and breast cancer patients Alessandra Graziottin *, Christian Singer **, Ernst Kubista **, Monique Visser *** and Herjan J.T. Coelingh Bennink *** * Professor at the University of Florence, Italy – Director, Center of Gynaecology, H San Raffaele Resnati, Milan, Italy ** Akademisches Krankenhaus Wien, Wien, Austria *** Pantarhei Bioscience, Zeist, The Netherlands Estetrol (E 4) is a foetal estrogen, produced by the foetal liver during pregnancy only. It has a selective ERalpha and ERbeta receptor bindin g with preference for ERalpha, with antagonist action. E 4 is present at 9 weeks of gestation, with exponential increase of synthesis and blood levels. At term the foetus produces about 3 mg/day. Elimination half-life is 28 hours. Potential applications in women’s life-span include: contraception, hormone replacement therapy (HRT), specifically for vasomotor symptoms, vulvovaginal atrophy and osteoporosis, and therapy of breast cancer. Preliminary data support its efficacy in the treatment of: hot flushes, with significant reduction; in the maturation of the vaginal mucosa, with significant increase of superficial cells at the cytological evaluation; a dose dependent effect on the endometrium: low doses such as 2 mg of Estetrol/day, sufficient to treat a number of symptoms, do not stimulate the endometrium; a significant protective effect on bone: this growing set of data suggest that E 4 could have a new, significant role in the treatment of menopausal symptoms, with an extraordinary safe profile.
    [Show full text]
  • Failures and Controversies of the Antiestrogen Treatment of Breast Cancer
    In: Estrogen Prevention for Breast Cancer ISBN: 978-1-62417-378-3 Editor: Zsuzsanna Suba © 2013 Nova Science Publishers, Inc. No part of this digital document may be reproduced, stored in a retrieval system or transmitted commercially in any form or by any means. The publisher has taken reasonable care in the preparation of this digital document, but makes no expressed or implied warranty of any kind and assumes no responsibility for any errors or omissions. No liability is assumed for incidental or consequential damages in connection with or arising out of information contained herein. This digital document is sold with the clear understanding that the publisher is not engaged in rendering legal, medical or any other professional services. Chapter VII Failures and Controversies of the Antiestrogen Treatment of Breast Cancer Zsuzsanna Suba National Institute of Oncology, Department of Surgical and Molecular Pathology, Budapest, Hungary Abstract In postmenopausal women, estrogens have unquestionable preventive and curative effects against atherogenic cardiovascular lesions, osteoporosis and neurodegenerative diseases. Moreover, recent studies on correlations between hormone replacement therapy and cancer risk could justify preventive, anticancer capacities of estrogen both on smoking associated and hormone related cancers. Experimental developing of antiestrogen compounds aimed to inhibit the binding of presumably harmful, endogenous estrogen to its receptor system so as to achieve a regression of hormone-related cancers. However, antiestrogens proved to be ineffective in the majority of selected receptor positive breast cancer cases and produced severe side effects, such as vascular complications and cancer development at several sites. Failure of antiestrogen therapy was designated as ―endocrine resistance‖ of tumors.
    [Show full text]
  • The Novel Progesterone Receptor
    0013-7227/99/$03.00/0 Vol. 140, No. 3 Endocrinology Printed in U.S.A. Copyright © 1999 by The Endocrine Society The Novel Progesterone Receptor Antagonists RTI 3021– 012 and RTI 3021–022 Exhibit Complex Glucocorticoid Receptor Antagonist Activities: Implications for the Development of Dissociated Antiprogestins* B. L. WAGNER†, G. POLLIO, P. GIANGRANDE‡, J. C. WEBSTER, M. BRESLIN, D. E. MAIS, C. E. COOK, W. V. VEDECKIS, J. A. CIDLOWSKI, AND D. P. MCDONNELL Department of Pharmacology and Cancer Biology (B.L.W., G.P., P.G., D.P.M.), Duke University Medical Center, Durham, North Carolina 27710; Molecular Endocrinology Group (J.C.W., J.A.C.), NIEHS, National Institutes of Health, Research Triangle Park, North Carolina 27709; Department of Biochemistry and Molecular Biology (M.B., W.V.V.), Louisiana State University Medical School, New Orleans, Louisiana 70112; Ligand Pharmaceuticals, Inc. (D.E.M.), San Diego, California 92121; Research Triangle Institute (C.E.C.), Chemistry and Life Sciences, Research Triangle Park, North Carolina 27709 ABSTRACT by agonists for DNA response elements within target gene promoters. We have identified two novel compounds (RTI 3021–012 and RTI Accordingly, we observed that RU486, RTI 3021–012, and RTI 3021– 3021–022) that demonstrate similar affinities for human progeste- 022, when assayed for PR antagonist activity, accomplished both of rone receptor (PR) and display equivalent antiprogestenic activity. As these steps. Thus, all three compounds are “active antagonists” of PR with most antiprogestins, such as RU486, RTI 3021–012, and RTI function. When assayed on GR, however, RU486 alone functioned as 3021–022 also bind to the glucocorticoid receptor (GR) with high an active antagonist.
    [Show full text]
  • Glucocorticoid Withdrawal—An Overview on When and How to Diagnose Adrenal Insufficiency in Clinical Practice
    diagnostics Review Glucocorticoid Withdrawal—An Overview on When and How to Diagnose Adrenal Insufficiency in Clinical Practice Katarzyna Pelewicz and Piotr Mi´skiewicz* Department of Internal Medicine and Endocrinology, Medical University of Warsaw, 02-091 Warsaw, Poland; [email protected] * Correspondence: [email protected]; Tel.: +48-225-992-877 Abstract: Glucocorticoids (GCs) are widely used due to their anti-inflammatory and immunosup- pressive effects. As many as 1–3% of the population are currently on GC treatment. Prolonged therapy with GCs is associated with an increased risk of GC-induced adrenal insufficiency (AI). AI is a rare and often underdiagnosed clinical condition characterized by deficient GC production by the adrenal cortex. AI can be life-threatening; therefore, it is essential to know how to diagnose and treat this disorder. Not only oral but also inhalation, topical, nasal, intra-articular and intravenous administration of GCs may lead to adrenal suppression. Moreover, recent studies have proven that short-term (<4 weeks), as well as low-dose (<5 mg prednisone equivalent per day) GC treatment can also suppress the hypothalamic–pituitary–adrenal axis. Chronic therapy with GCs is the most com- mon cause of AI. GC-induced AI remains challenging for clinicians in everyday patient care. Properly conducted GC withdrawal is crucial in preventing GC-induced AI; however, adrenal suppression may occur despite following recommended GC tapering regimens. A suspicion of GC-induced AI requires careful diagnostic workup and prompt introduction of a GC replacement treatment. The Citation: Pelewicz, K.; Mi´skiewicz,P. present review provides a summary of current knowledge on the management of GC-induced AI, Glucocorticoid Withdrawal—An including diagnostic methods, treatment schedules, and GC withdrawal regimens in adults.
    [Show full text]
  • Biotransformation: Basic Concepts (1)
    Chapter 5 Absorption, Distribution, Metabolism, and Elimination of Toxics Biotransformation: Basic Concepts (1) • Renal excretion of chemicals Biotransformation: Basic Concepts (2) • Biological basis for xenobiotic metabolism: – To convert lipid-soluble, non-polar, non-excretable forms of chemicals to water-soluble, polar forms that are excretable in bile and urine. – The transformation process may take place as a result of the interaction of the toxic substance with enzymes found primarily in the cell endoplasmic reticulum, cytoplasm, and mitochondria. – The liver is the primary organ where biotransformation occurs. Biotransformation: Basic Concepts (3) Biotransformation: Basic Concepts (4) • Interaction with these enzymes may change the toxicant to either a less or a more toxic form. • Generally, biotransformation occurs in two phases. – Phase I involves catabolic reactions that break down the toxicant into various components. • Catabolic reactions include oxidation, reduction, and hydrolysis. – Oxidation occurs when a molecule combines with oxygen, loses hydrogen, or loses one or more electrons. – Reduction occurs when a molecule combines with hydrogen, loses oxygen, or gains one or more electrons. – Hydrolysis is the process in which a chemical compound is split into smaller molecules by reacting with water. • In most cases these reactions make the chemical less toxic, more water soluble, and easier to excrete. Biotransformation: Basic Concepts (5) – Phase II reactions involves the binding of molecules to either the original toxic molecule or the toxic molecule metabolite derived from the Phase I reactions. The final product is usually water soluble and, therefore, easier to excrete from the body. • Phase II reactions include glucuronidation, sulfation, acetylation, methylation, conjugation with glutathione, and conjugation with amino acids (such as glycine, taurine, and glutamic acid).
    [Show full text]
  • Efficacy and Safety of the Selective Glucocorticoid Receptor Modulator
    Efficacy and Safety of the Selective Glucocorticoid Receptor Modulator, Relacorilant (up to 400 mg/day), in Patients With Endogenous Hypercortisolism: Results From an Open-Label Phase 2 Study Rosario Pivonello, MD, PhD1; Atil Y. Kargi, MD2; Noel Ellison, MS3; Andreas Moraitis, MD4; Massimo Terzolo, MD5 1Università Federico II di Napoli, Naples, Italy; 2University of Miami Miller School of Medicine, Miami, FL, USA; 3Trialwise, Inc, Houston, TX, USA; 4Corcept Therapeutics, Menlo Park, CA, USA; 5Internal Medicine 1 - San Luigi Gonzaga Hospital, University of Turin, Orbassano, Italy INTRODUCTION EFFICACY ANALYSES Table 5. Summary of Responder Analysis in Patients at Last SAFETY Relacorilant is a highly selective glucocorticoid receptor modulator under Key efficacy assessments were the evaluation of blood pressure in the Observation Table 7 shows frequency of TEAEs; all were categorized as ≤Grade 3 in hypertensive subgroup and glucose tolerance in the impaired glucose severity investigation for the treatment of all etiologies of endogenous Cushing Low-Dose Group High-Dose Group tolerance (IGT)/type 2 diabetes mellitus (T2DM) subgroup Five serious TEAEs were reported in 4 patients in the high-dose group syndrome (CS) Responder, n/N (%) Responder, n/N (%) o Relacorilant reduces the effects of cortisol, but unlike mifepristone, does o Response in hypertension defined as a decrease of ≥5 mmHg in either (pilonidal cyst, myopathy, polyneuropathy, myocardial infarction, and not bind to progesterone receptors (Table 1)1 mean systolic blood pressure (SBP) or diastolic blood pressure (DBP) from HTN 5/12 (41.67) 7/11 (63.64) hypertension) baseline No drug-induced cases of hypokalemia or abnormal vaginal bleeding were IGT/T2DM 2/13 (15.38) 6/12 (50.00) o Response in IGT/T2DM defined by one of the following: noted Table 1.
    [Show full text]
  • Breast Disorders in Girls and Adolescents. Is There a Need for a Specialized Service?
    Original Study Breast Disorders in Girls and Adolescents. Is There a Need for a Specialized Service? Lina Michala MRCOG, PhD *, Alexandra Tsigginou MD, PhD, Dimitris Zacharakis MD, Constantine Dimitrakakis MD, PhD 1stDepartment of Obstetrics and Gynaecology, University of Athens, Alexandra Hospital, Athens, Greece abstract Introduction: Minor breast concerns in childhood and adolescence are common and lead to increased anxiety among young patients and their families, particularly due to high correlation with breast cancer. However, most breast services aim at managing adults and triaging patients with breast cancer, whereas adolescent medicine specialists or pediatricians are usually not appropriately trained to identify and treat breast pathology. Methods: We reviewed hospital records of all patients attending a pediatric and adolescent gynecology or breast clinic of a tertiary referral hospital, with a breast related symptom, between January 2009 and December 2011. We collected information regarding age at presen- tation, age at menarche, diagnosis, management and outcome. Results: We identified 81 patients of which 11 presented with an abnormal nipple or areolar secretion, 33 had a palpable lump, 20 had mastitis, and 16 had unequal breast development. One patient presented with virginal breast hypertrophy. Three out of 11 of the patients with an abnormal secretion had a cyst identified on ultrasonography. Out of the palpable lumps 12 were fibroadenomas, 3 were phyllodes tumors, and 14 were cystic in nature. The phyllodes tumors and half of the fibroadenomas were removed. The remaining fibroadenomas remain under regular ultrasonographic follow-up. All cases of mastitis were treated conservatively and resolved with broad spectrum antibiotic treatment. Conclusion: In our series, no malignancies were identified.
    [Show full text]
  • Cirugía De La Mama
    25,5 mm 15 GUÍAS CLÍNICAS DE LA ASOCIACIÓN ESPAÑOLA DE CIRUJANOS 15 CIRUGÍA DE LA MAMA Fernando Domínguez Cunchillos Sapiña Juan Blas Ballester Parga Gonzalo de Castro Fernando Domínguez Cunchillos Juan Blas Ballester Sapiña Gonzalo de Castro Parga CIRUGÍA DE LA MAMA CIRUGÍA SECCIÓN DE PATOLOGÍA DE LA MAMA Portada AEC Cirugia de la mama.indd 1 17/10/17 17:47 Guías Clínicas de la Asociación Española de Cirujanos CIRUGÍA DE LA MAMA EDITORES Fernando Domínguez Cunchillos Juan Blas Ballester Sapiña Gonzalo de Castro Parga SECCIÓN DE PATOLOGÍA DE LA MAMA © Copyright 2017. Fernando Domínguez Cunchillos, Juan Blas Ballester Sapiña, Gonzalo de Castro Parga. © Copyright 2017. Asociación Española de Cirujanos. © Copyright 2017. Arán Ediciones, S.L. Castelló, 128, 1.º - 28006 Madrid e-mail: [email protected] http://www.grupoaran.com Reservados todos los derechos. Esta publicación no puede ser reproducida o transmitida, total o parcialmente, por cualquier medio, electrónico o mecánico, ni por fotocopia, grabación u otro sistema de reproducción de información sin el permiso por escrito de los titulares del Copyright. El contenido de este libro es responsabilidad exclusiva de los autores. La Editorial declina toda responsabilidad sobre el mismo. ISBN 1.ª Edición: 978-84-95913-97-5 ISBN 2.ª Edición: 978-84-17046-18-7 Depósito Legal: M-27661-2017 Impreso en España Printed in Spain CIRUGÍA DE LA MAMA EDITORES F. Domínguez Cunchillos J. B. Ballester Sapiña G. de Castro Parga AUTORES A. Abascal Amo M. Fraile Vasallo B. Acea Nebril G. Freiría Barreiro J. Aguilar Jiménez C. A. Fuster Diana L.
    [Show full text]
  • 29 June 2016 09 :30 – 09 :55 : Registration 09 :55 – 10 :00 : Welcome 10 :00 – 10 :30 : the Unique Potential of Estetrol
    investor day 2016 29 June 2016 09 :30 – 09 :55 : Registration 09 :55 – 10 :00 : Welcome 10 :00 – 10 :30 : The unique potential of Estetrol 10 :30 – 11 :45Programme: Mithra’sde la journée strategy 11 :45 – 12 :00 : Q&A 12 :00 – 13 :30 : Drink and lunch with Executive Management 13 :30 – 14 :15 : Focus on Estetrol-based projects 14 :15 – 14 :30 : Coffee break 14 :30 – 15 :15 : Focus on long-acting drugs and Mithra CDMO 15 :15 – 15 :30 : Q&A and wrap-up session 15 :30 – 16 :30 : Drink and networking What is Estetrol ? Interview with Professor J.M. Foidart MD. Member of scientific committee Mithra Professor J.M. Foidart MD. Member of scientific committee Mithra 4 Estrogens in the “pill” a very limited family . Estradiol . Synthetic progestin . Ethinylestradiol Over 95% of oral contraceptives contain ethinylestradiol 6 Synthetic Progestins : a very large family First First Second Third New” COCs generation: generation: generation: progestins: > Norethisterone > Norethynodrel > Norgestrel > Desogestrel > Drospirenone > Norethinodrel > Nortestosterone > Levonorgestrel > Etonogestrel > Dienogest > High doses of derivatives > Gestodene > Trimestone synthetic estrogen >Pregnanes > Nesterone and androgenic > Norgestimate > Nomegestrol Ac. progestin > Promegestone Jan 2014 EMA classification progestins by type . Structural modification: to reduce androgenic side-effects but maintain strong progestational activity . Wider health benefits depending on progestin properties Reviewed in Brynhildsen J. Ther Adv Drug Saf. 2014;5(5):201-13; Benagiano7 G, et al. Eur J Contracept Reprod Health Care. 2004;9(3):182- 93; Sitruk-Ware R. Hum Reprod Update. 2006;12(2):169-78; Micks E, et al. Endocr Connect. 2015;4(4):R81-92 The third and fourth generation progestins and pills are not androgenic.
    [Show full text]